0G99 Oxurion NV

LSE · GB · Healthcare · Biotechnology · oxurion.com

—Mkt Cap: —P/E: —682d ago

Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$126.58BUSDP/E 29.1

MRNA

Moderna, Inc. - Common Stock

$87.04BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

argenx SE - American Depositary Shares

BeOne Medicines Ltd. - American Depositary Shares

$41.99BUSDP/E 66.0

RVMD

Revolution Medicines, Inc. - Common Stock

$38.14BUSD

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$35.22BUSDP/E 32.4

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$31.02BUSDP/E 39.1

ROIV

Roivant Sciences Ltd. - Common Shares

Incyte Corporation - Common Stock

$22.92BUSDP/E 14.4

GMAB

Genmab A/S - American Depositary Shares

$22.75BUSDP/E 29.1

BNTX

BioNTech SE - American Depositary Shares

$22.03BUSD

INSM

Insmed Incorporated - Common Stock

$21.02BUSD

EXEL

Exelixis, Inc. - Common Stock

$15.42BUSDP/E 19.6

ASND

Ascendis Pharma A/S - Ordinary Share

$14.82BUSDP/E 17.3

HALO

Halozyme Therapeutics, Inc. - Common Stock

$13.83BUSDP/E 35.6

Key Statistics

Company

Market Cap—

Enterprise Value41.33M USD

Revenue (TTM)1.29M USD

Gross Profit1.28M USD

Net Income (TTM)-3.89M USD

Revenue/Share0.02 EUR

Last Price—

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees26

CountryGB

SectorHealthcare

IndustryBiotechnology

ISINBE0003846632

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-16.57

EV/Revenue32.05

P/S—

P/B-1.86

EPS (TTM)-0.76

EPS (Forward)—

52W Range

—

52W High—

52W Low—

Profitability

Gross Margin99.39%

Oper. Margin-127.75%

EBITDA Margin-193.46%

Profit Margin0.00%

ROE—

ROA-33.45%

ROIC—

ROCE—

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-1.29M USD

CapEx (TTM)—

FCF Margin-127.89%

FCF Yield—

Net Debt12.92M USD

Net Debt/EBITDA-5.18

Net Debt/FCF—

Balance Sheet

Debt/Equity—

Current Ratio0.09

Quick Ratio0.09

Book Value/Sh-0.15 EUR

Cash/Share0.00 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.38.27M

Float78.71M

Insiders16.29%

Institutions0.00%

Technical

SMA 500.0019 EUR

SMA 2000.0045 EUR

Beta0.07

S&P 52W Chg13.72%

Avg Vol (30d)—

Avg Vol (10d)2.83M

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—